CoChat

Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review

Open access
Dias, Denise Deo, Vasconcelos, Andrea Rodrigues, Souza, Ana Carolina Remondi, Menezes, Caroline de, Silva, Isabella Sobral Teixeira e, Name, José João · 2025 · Obesities

The DOI matches its Crossref record; 304 of the 332 references it cites were found in a registry or an index, and 21 are not checked yet; 105 of the 438 sources its claims cite were checked for support.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective in the management of obesity; however, their efficacy and tolerability may be further optimized through complementary nutritional strategies. Such interventions may address key challenges associated with GLP-1RA therapy, including gastrointestinal adverse effects, lean mass loss, and reduced long-term adherence leading to weight regain. Evidence from preclinical and clinical studies indicates that omega-3 polyunsaturated fatty acids may enhance the metabolic benefits of GLP-1RAs and attenuate lean mass loss, primarily via anti-inflammatory pathways and modulation of protein synthesis. Synergistic effects have also been reported with other bioactive compounds—such as flavonoids and anthocyanins, which improve metabolic outcomes; probiotics and prebiotics, which may alleviate gastrointestinal intolerance; and high-quality protein sources, which support body composition preservation. Collectively, these findings suggest that nutritional adjuncts may complement GLP-1RA therapies through convergent physiological mechanisms, including the regulation of inflammation, gut microbiome composition, and cellular metabolism. While current data highlight the promise of integrated pharmaco-nutritional strategies as adjuncts to GLP-1-based obesity therapy, further randomized controlled trials are needed to establish the most effective interventions and protocols.

Verified 2026-11-19 · 21 references not checked yet

Overview

CoChat Summary

TL;DR

This narrative review argues that nutritional adjuncts—fiber/prebiotics, probiotics, protein sources, specific nutrients, and botanical actives—may complement GLP-1 receptor agonist (GLP-1RA) therapy in obesity by improving GI tolerability, preserving lean mass, and amplifying metabolic benefits. However, direct clinical evidence combining these interventions with GLP-1RAs remains scarce, and most proposed synergies are based on indirect, preclinical, or expert-consensus evidence.

Key findings

  • GLP-1RAs achieve placebo-adjusted weight loss of 8–21% after one year, but long-term effectiveness is limited by GI adverse events affecting up to 70–85% of patients, nutritional deficiencies, lean mass loss, and weight regain—with up to two-thirds of lost weight returning within one year after discontinuation.
  • Nutritional adjuncts with the strongest practice-reasonable support include adequate protein intake, ginger, dietary fiber, and probiotics for preserving lean mass and improving GI tolerability; expert consensus recommends fiber for constipation and probiotics for persistent diarrhea during GLP-1RA treatment.
  • Specific evidence cited includes a pilot study of 27 obese patients where a multispecies probiotic plus low-dose liraglutide produced comparable weight loss to higher-dose liraglutide alone, with 59.3% reporting only mild transient GI symptoms and none discontinuing, versus an 80.3% adverse-event incidence in a comparable high-dose liraglutide trial.
  • Other reported findings include L. gasseri BNR17 producing a ~22 cm² decrease in visceral adiposity versus placebo; oral glutamine (15 g/day) achieving ≥50-point IBS severity score reduction in 79.6% vs 5.8% with placebo; and omega-3/krill oil trials showing muscle function or lean-mass benefits, though omega-3 evidence is described as mixed.

Methods

  • Narrative review with a targeted, non-systematic search in PubMed, Scopus, Google Scholar, and Cochrane up to September 2025, plus manual reference searching.
  • Search terms included “GLP-1,” “GLP-1 receptor agonists,” drug names (semaglutide, liraglutide, tirzepatide), intervention descriptors (“nutrition,” “dietary interventions,” “nutraceuticals”), and specific actives (“probiotics,” “fibers,” “botanical extracts”).
  • The review prioritized English-language clinical and preclinical studies reporting metabolic and/or GI tolerability outcomes relevant to GLP-1RA therapy, synthesizing preclinical, indirect clinical, and direct clinical findings when available.

Limitations

  • The paper states that direct clinical evidence combining nutritional interventions with GLP-1RAs remains limited, that many compounds have not been studied in combination with GLP-1RAs, and that further randomized controlled trials are needed to establish effective interventions and protocols.
  • The paper notes that nutritional supplements differ from pharmacological agents in regulatory classification and are not subject to the same pre-market clinical validation, and advises caution in vulnerable populations such as pregnant/lactating women, older adults, critically ill patients, and those with hepatic or renal impairment.
  • Evident from the text: the search was non-systematic, with no described protocol, risk-of-bias assessment, or formal evidence grading; many proposed benefits rely on preclinical data, studies in non-GLP-1RA populations, or expert consensus, so several adjunctive roles remain hypothetical.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/obesities5040088

Cites

304 of 332 references verified0 citation errors · 7 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1 Main actions of GLP-1RAs in the human body that may synergize with nutritional adjuncts. Positive/desired effects that may be potentiated are shown in blue, whereas challenges that could be mitigated by nutritional interventions are shown in red. Nutritional adjuncts are labeled with the same letters as the GLP-1RA effects to indicate potential sites of synergy. Abbreviations: BMI, body mass index; CNS, central nervous system; cRG-I, carrot-derived rhamnogalacturonan-I; GI, gastrointestinal; GLP-1RA, glucagon-like peptide-1 receptor agonist; GOS, galacto-oligosaccharide; HbA1c, glycated hemoglobin; LDL, low density lipoprotein; PUFA, polyunsaturated fatty acid; SCFA, short-chain fatty acid; TC, total cholesterol; TG, triglycerides. Symbols: ↑ denotes increase; ↓ denotes decrease.
Figure 1 Main actions of GLP-1RAs in the human body that may synergize with nutritional adjuncts. Positive/desired effects that may be potentiated are shown in blue, whereas challenges that could be mitigated by nutritional interventions are shown in red. Nutritional adjuncts are labeled with the same letters as the GLP-1RA effects to indicate potential sites of synergy. Abbreviations: BMI, body mass index; CNS, central nervous system; cRG-I, carrot-derived rhamnogalacturonan-I; GI, gastrointestinal; GLP-1RA, glucagon-like peptide-1 receptor agonist; GOS, galacto-oligosaccharide; HbA1c, glycated hemoglobin; LDL, low density lipoprotein; PUFA, polyunsaturated fatty acid; SCFA, short-chain fatty acid; TC, total cholesterol; TG, triglycerides. Symbols: ↑ denotes increase; ↓ denotes decrease.CC-BY · From the PDF
Figure 2 Proposed mechanisms by which nutritional interventions may exert effects relevant to GLP-1RA therapy. Nutritional strategies targeting gut, metabolic, and inflammatory pathways may modulate GLP-1RA-related outcomes in glycemic control, body composition, gastrointestinal tolerance, and cardiometabolic health. The figure illustrates key physiological domains, representative nutritional compounds, and their putative mechanisms of action. Abbreviations: AKT, protein kinase B; AMPK, AMP-activated protein kinase; CCK, cholecystokinin; CNS, central nervous system; eNOS, endothelial nitric oxide synthase; FGF21, fibroblast growth factor-21; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; hs-CRP, high-sensitivity C-reactive protein; IGF-1, insulin-like growth factor-1; IL, interleukin; LDL-c, low-density lipoprotein cholesterol; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; NO, nitric oxide; PI3K, phosphatidylinositol-3-kinase; PPAR, peroxisome proliferator-activated receptors; PYY, peptide YY; SCFA, short-chain fatty acid; SREBP-1c, sterol-regulatory element-binding protein-1; TNF, tumor necrosis factor; TRPV1, transient-receptor potential vanilloid 1; UCP, uncoupling protein. Symbols: ↑ denotes increase; ↓ denotes decrease.
Figure 2 Proposed mechanisms by which nutritional interventions may exert effects relevant to GLP-1RA therapy. Nutritional strategies targeting gut, metabolic, and inflammatory pathways may modulate GLP-1RA-related outcomes in glycemic control, body composition, gastrointestinal tolerance, and cardiometabolic health. The figure illustrates key physiological domains, representative nutritional compounds, and their putative mechanisms of action. Abbreviations: AKT, protein kinase B; AMPK, AMP-activated protein kinase; CCK, cholecystokinin; CNS, central nervous system; eNOS, endothelial nitric oxide synthase; FGF21, fibroblast growth factor-21; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; hs-CRP, high-sensitivity C-reactive protein; IGF-1, insulin-like growth factor-1; IL, interleukin; LDL-c, low-density lipoprotein cholesterol; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; NO, nitric oxide; PI3K, phosphatidylinositol-3-kinase; PPAR, peroxisome proliferator-activated receptors; PYY, peptide YY; SCFA, short-chain fatty acid; SREBP-1c, sterol-regulatory element-binding protein-1; TNF, tumor necrosis factor; TRPV1, transient-receptor potential vanilloid 1; UCP, uncoupling protein. Symbols: ↑ denotes increase; ↓ denotes decrease.CC-BY · From the PDF

Verification

Claims the paper makes

24 Valid · 41 Not valid · 244 Not checked · 59 Own results and interpretations

210 more claims · 42 with their cited sources checked

Create a free account to see all 368 claims and to verify the 333 references still open.

See all claims — free account
  • It may state two separate claims as one. 138
  • Probably not a substantial claim. 20
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Research works printed but not linked: 13

  1. Choi, 2019, Oral Collagen Supplementation: A Systematic Review of Dermatological Applications, J. Drugs Dermatol., 18, 9
  2. Modi, M., and Modi, K. (2025, November 19). Ginger Root, StatPearls, Available online: https://www.ncbi.nlm.nih.gov/books/NBK565886/.
  3. Guarneiri, 2025, Investigation of the Influence of a Bitter Melon Product on Indicators of Cardiometabolic Health in Adults with Prediabetes, J. Am. Nutr. Assoc., 44, 306
  4. Deguchi, 2000, Effectiveness of consecutive ingestion and excess intake of guava leaves tea in human volunteers, J. Jpn. Council. Adv. Food Ingred. Res., 3, 19
  5. Giacosa, 2015, Can nausea and vomiting be treated with ginger extract?, Eur. Rev. Med. Pharmacol. Sci., 19, 1291
  6. Pongrojpaw, 2007, A randomized comparison of ginger and dimenhydrinate in the treatment of nausea and vomiting in pregnancy, J. Med. Assoc. Thail., 90, 1703
  7. Dayib, 2020, Dietary fibers reduce obesity-related disorders: Mechanisms of action, Curr. Opin. Clin. Nutr. Metab. Care, 23, 445
  8. Barakat, 2020, Bovine Colostrum in the Treatment of Acute Diarrhea in Children: A Double-Blinded Randomized Controlled Trial, J. Trop. Pediatr., 66, 46
  9. Kannappan, 2006, Cinnamon bark extract improves glucose metabolism and lipid profile in the fructose-fed rat, Singap. Med. J., 47, 858
  10. Javed, 2012, Lipid lowering effect of Cinnamomum zeylanicum in hyperlipidaemic albino rabbits, Pak. J. Pharm. Sci., 25, 141
  11. Ahmad, 2025, Ameliorating implications of Psidium guajava L. (guava) leaf against metabolic syndromes—A review, J. Agric. Food Res., 21, 101867
  12. Amin, A.N., Intang, I.N., and Alfira, N. (2024). Effect of guajava (Psidium) leaves decoction on changes in blood glucose levels of people with diabetes mellitus. Proc. Optim., 1.
  13. Salaramoli, 2022, The effects of ginger and its constituents in the prevention of metabolic syndrome: A review, Iran. J. Basic Med. Sci., 25, 664

Cited by

See all 13

Metadata

Authors
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J.
Affiliations
Kilyos Assessoria, Cursos e Palestras, São Paulo 01311-100, Brazil
Corresponding author
Name, José João
Venue
Obesities
Publisher
MDPI AG
Published
2025-12-02
Volume
5
Issue
4
Pages
88
ISSN
2673-4168 (ISSN-L)
OpenAlex
W4417124127
Cited by
8
References
324
Citations by year
2026: 8
FWCI
1.09
Type
journal article
Language
en
Open access
Locations
  • Obesities (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor agonists, obesity, omega-3 polyunsaturated fatty acids, lean mass loss, gastrointestinal adverse effects, weight regain, probiotics and prebiotics, flavonoids, anthocyanins, high-quality protein, gut microbiota, inflammation, body composition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.